KR20240006692A - 치환된 1,2-디아미노 헤테로사이클릭 화합물 유도체의 제조 및 그의 약제로서의 용도 - Google Patents

치환된 1,2-디아미노 헤테로사이클릭 화합물 유도체의 제조 및 그의 약제로서의 용도 Download PDF

Info

Publication number
KR20240006692A
KR20240006692A KR1020237043163A KR20237043163A KR20240006692A KR 20240006692 A KR20240006692 A KR 20240006692A KR 1020237043163 A KR1020237043163 A KR 1020237043163A KR 20237043163 A KR20237043163 A KR 20237043163A KR 20240006692 A KR20240006692 A KR 20240006692A
Authority
KR
South Korea
Prior art keywords
alkyl
mmol
compound
optionally substituted
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237043163A
Other languages
English (en)
Korean (ko)
Inventor
백기선
구자혁
최순규
박영환
사이먼 워드
대런 르 그랑
라이언 웨스트
페넬로페 터너
사무엘 마라마이
트리스탄 레우일론
Original Assignee
아벨로스테라퓨틱스 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아벨로스테라퓨틱스 주식회사 filed Critical 아벨로스테라퓨틱스 주식회사
Publication of KR20240006692A publication Critical patent/KR20240006692A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020237043163A 2021-06-09 2022-06-09 치환된 1,2-디아미노 헤테로사이클릭 화합물 유도체의 제조 및 그의 약제로서의 용도 Pending KR20240006692A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2108249.0A GB202108249D0 (en) 2021-06-09 2021-06-09 Compounds
GB2108249.0 2021-06-09
PCT/KR2022/008105 WO2022260441A1 (en) 2021-06-09 2022-06-09 Preparation of substituted 1,2-diaminoheterocyclic compound derivatives and their use as pharmaceutical agents

Publications (1)

Publication Number Publication Date
KR20240006692A true KR20240006692A (ko) 2024-01-15

Family

ID=76838874

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237043163A Pending KR20240006692A (ko) 2021-06-09 2022-06-09 치환된 1,2-디아미노 헤테로사이클릭 화합물 유도체의 제조 및 그의 약제로서의 용도

Country Status (10)

Country Link
US (1) US20240300936A1 (https=)
EP (1) EP4352049A4 (https=)
JP (1) JP2024522201A (https=)
KR (1) KR20240006692A (https=)
CN (1) CN117529476A (https=)
AU (1) AU2022291332A1 (https=)
CA (1) CA3216629A1 (https=)
GB (1) GB202108249D0 (https=)
MX (1) MX2023014784A (https=)
WO (1) WO2022260441A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250096877A (ko) * 2022-12-12 2025-06-27 아벨로스테라퓨틱스 주식회사 치환된 헤테로고리 화합물 유도체 및 그의 약학적 용도
WO2024137979A2 (en) * 2022-12-23 2024-06-27 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Foxm1 inhibitors and their use in treating cancers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2465405A (en) * 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
JP5743897B2 (ja) * 2008-11-20 2015-07-01 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 化合物
JP5856151B2 (ja) * 2010-05-12 2016-02-09 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼ阻害剤として有用な２−アミノピリジン誘導体
US9481670B2 (en) * 2011-01-25 2016-11-01 Sphaera Pharma Pte. Ltd. Triazine compounds
US9604937B2 (en) * 2012-11-27 2017-03-28 Thomas Helledays Stiftelse For Medicinsk Forskning Pyrimidine-2,4-diamine derivatives for treatment of cancer
CN106794181A (zh) * 2014-06-04 2017-05-31 托马斯·黑勒戴药物研究基金会 用于治疗炎性和自身免疫性病况的mth1抑制剂

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Mol. Biol. Cell. 20(22): 4777-89
Mol. Cell 52 393-405
Science 330 1673-1677

Also Published As

Publication number Publication date
EP4352049A4 (en) 2025-05-21
EP4352049A1 (en) 2024-04-17
CN117529476A (zh) 2024-02-06
WO2022260441A1 (en) 2022-12-15
JP2024522201A (ja) 2024-06-11
GB202108249D0 (en) 2021-07-21
CA3216629A1 (en) 2022-12-15
US20240300936A1 (en) 2024-09-12
AU2022291332A1 (en) 2023-12-21
MX2023014784A (es) 2024-03-25

Similar Documents

Publication Publication Date Title
EP4306529B1 (en) Fgfr inhibitors and methods of use thereof
AU2017311645B2 (en) Pyridopyrimdinone CDK2/4/6 inhibitors
CN115996929B (zh) 腺苷A2a受体的拮抗剂
CA3084090A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
TW201934548A (zh) 甲醯胺化合物及其用途
TW201904959A (zh) 雜環化合物
KR20170066566A (ko) Btk 억제제로서 헤테로아릴 화합물 및 이들의 용도
EP3068784A1 (en) Substituted 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine derivatives as casein kinase 1 d/e inhibitors
EP3694331B1 (en) Indazolyl-spiro[2.3]hexane-carbonitrile derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
TW202019899A (zh) Tlr7/8拮抗劑及其用途
AU2016287335A1 (en) TBK/IKKepsilon inhibitor compounds and uses thereof
CN112930213A (zh) 用作布鲁顿酪氨酸激酶(btk)的可逆抑制剂的稠合咪唑并吡啶
TW202122382A (zh) 乙內醯脲衍生物
CA3049820A1 (en) Compounds for inhibiting lrrk2 kinase activity
KR20150090044A (ko) 아자퀴나졸린 카복사미드 유도체
CA2958508A1 (en) Indazoles
KR20240006692A (ko) 치환된 1,2-디아미노 헤테로사이클릭 화합물 유도체의 제조 및 그의 약제로서의 용도
WO2020116662A1 (ja) シクロアルカン−１，３−ジアミン誘導体
CA3119882A1 (en) Heterocyclic spiro-compounds as am2 receptor inhibitors
CA3119886A1 (en) Heterocyclic spiro-compounds as am2 receptor inhibitors
US20250352549A1 (en) Substituted heterocyclic compound derivatives and their pharmaceutical use
CN116249696B (zh) 嘧啶酮类化合物及其用途
EA036060B1 (ru) Пиридопиримидиноновые ингибиторы cdk2/4/6
CA3269027A1 (en) Azole derivatives as shp2 inhibitors
TW202545531A (zh) 氮—喹唑啉化合物之使用方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000